138 related articles for article (PubMed ID: 21493872)
1. Decision tree-based modeling of androgen pathway genes and prostate cancer risk.
Barnholtz-Sloan JS; Guan X; Zeigler-Johnson C; Meropol NJ; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1146-55. PubMed ID: 21493872
[TBL] [Abstract][Full Text] [Related]
2. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
[TBL] [Abstract][Full Text] [Related]
4. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
Stone A; Ratnasinghe LD; Emerson GL; Modali R; Lehman T; Runnells G; Carroll A; Carter W; Barnhart S; Rasheed AA; Greene G; Johnson DE; Ambrosone CB; Kadlubar FF; Lang NP
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1257-61. PubMed ID: 15894682
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
7. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer.
Irvine RA; Yu MC; Ross RK; Coetzee GA
Cancer Res; 1995 May; 55(9):1937-40. PubMed ID: 7728763
[TBL] [Abstract][Full Text] [Related]
8. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
9. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Choi SY; Kim HJ; Cheong HS; Myung SC
Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
[TBL] [Abstract][Full Text] [Related]
10. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.
Gilligan T; Manola J; Sartor O; Weinrich SP; Moul JW; Kantoff PW
Clin Prostate Cancer; 2004 Sep; 3(2):98-103. PubMed ID: 15479493
[TBL] [Abstract][Full Text] [Related]
11. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
12. Inherited variation in hormone-regulating genes and prostate cancer survival.
Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
[TBL] [Abstract][Full Text] [Related]
13. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
14. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms and prostate cancer risk.
Gsur A; Feik E; Madersbacher S
World J Urol; 2004 Feb; 21(6):414-23. PubMed ID: 14648103
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
[TBL] [Abstract][Full Text] [Related]
18. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Vaarala MH; Mattila H; Ohtonen P; Tammela TL; Paavonen TK; Schleutker J
Int J Cancer; 2008 Jun; 122(11):2511-6. PubMed ID: 18306354
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
[TBL] [Abstract][Full Text] [Related]
20. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
Ingles SA; Ross RK; Yu MC; Irvine RA; La Pera G; Haile RW; Coetzee GA
J Natl Cancer Inst; 1997 Jan; 89(2):166-70. PubMed ID: 8998186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
